Petrisli E, Chiereghin A, Gabrielli L, Zanfi C, Lauro A, Piccirilli G, Baccolini F, Altimari A, Bagni A, Cescon M, Pinna A D, Landini M P, Lazzarotto T
St.Orsola Malpighi General Hospital, University of Bologna, Bologna, Italy.
Transplant Proc. 2010 Jan-Feb;42(1):74-8. doi: 10.1016/j.transproceed.2009.12.032.
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are the major causes of graft failure and posttransplantation mortality among small bowel and multivisceral transplantations (SB/MVT). Little is known about human herpes virus 6 (HHV-6) infections in transplant recipients.
The purposes of this study were to analyze the clinical relevance of CMV, EBV, and HHV-6 infections after small bowel transplantation and to establish whether routine monitoring for HHV-6 infection should be recommended for the prevention of severe complications in this population.
Ten adult patients were monitored based on CMV, EBV, and HHV6 DNA quantifications in blood and biopsy tissue samples. Three patients were monitored for at least 5 months (early period) and 7 patients were monitored for 1 to 5 years after transplantation (late period).
In the early period, despite prophylaxis all 3 patients developed symptomatic CMV infections: 1 fever/diarrhea, 1 enteritis and rejection, as well as 1 fever and pneumonia. Only 1 patient developed EBV and HHV-6 infections. The average time of onset of CMV infection was 3 months after transplantation and only 24 days for HHV6 infection. In the late period, of the 7 SB/MVT recipients only 1 developed an EBV infection at 2 years after transplantation. No CMV or HHV-6 infections were identified in any patient.
CMV infection is a major cause of organ disease and rejection in the early period after transplantation. EBV infection in adult recipients must be considered also in the late period, particularly in association with severe immunosuppression. Because HHV-6 infection occurs earlier than CMV/EBV, it may serve as an indicator for more intense virological surveillance.
巨细胞病毒(CMV)和爱泼斯坦-巴尔病毒(EBV)是小肠和多脏器移植(SB/MVT)中移植物功能衰竭及移植后死亡的主要原因。关于移植受者中人类疱疹病毒6型(HHV-6)感染的情况所知甚少。
本研究旨在分析小肠移植后CMV、EBV和HHV-6感染的临床相关性,并确定是否应建议对HHV-6感染进行常规监测以预防该人群发生严重并发症。
对10例成年患者的血液和活检组织样本进行CMV、EBV和HHV-6 DNA定量监测。3例患者监测至少5个月(早期),7例患者在移植后监测1至5年(晚期)。
在早期,尽管进行了预防,所有3例患者均发生了有症状的CMV感染:1例发热/腹泻,1例肠炎和排斥反应,以及1例发热和肺炎。仅1例患者发生了EBV和HHV-6感染。CMV感染的平均发病时间为移植后3个月,HHV-6感染为24天。在晚期,7例SB/MVT受者中仅1例在移植后2年发生了EBV感染。未在任何患者中发现CMV或HHV-6感染。
CMV感染是移植后早期器官疾病和排斥反应的主要原因。成年受者的EBV感染在晚期也必须予以考虑,尤其是在伴有严重免疫抑制的情况下。由于HHV-6感染比CMV/EBV更早发生,它可能作为更强化病毒学监测的一个指标。